%0 Journal Article
%T A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE£¿) antibody construct, in patients with refractory solid tumors
%A Andrea Kratzer
%A Annette Hasenburg
%A Barbara Ritter
%A Beate Rautenberg
%A Djordje Atanackovic
%A Dorothea Wessiepe
%A Eva Vieser
%A Ingrid Patzak
%A James B. Rottman
%A Marie-Elisabeth Goebeler
%A Martin Wolf
%A Matthias Friedrich
%A Maxim Kebenko
%A Ruth Seggewiss-Bernhardt
%A Sabine Stienen
%A Stefanie Elm
%A Walter Fiedler
%J Archive of "Oncoimmunology".
%D 2018
%R 10.1080/2162402X.2018.1450710
%K AMG 110
%K solitomab
%K MT110
%K immunotherapy
%K bispecific
%K BiTE£¿
%K EpCAM
%K phase 1
%K solid tumor
%K CD3
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136859/